DNA Methylation & Chromatin Modifications: Mechanisms & Applications in Cancer*

DNA甲基化

• 批准号: 6964121
• 负责人: SAMSON T JACOB
• 金额: $ 224.85万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-27 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6964121
• 关键词: DNA methylation; chromatin; clinical research; clinical trials; epigenetics; gene expression; gene targeting; genes; genetics; histones; methylation; neoplasm /cancer; pharmacokinetics; suppression

DESCRIPTION (provided by applicant): The long-term objective of this Program Project Grant application is to advance our basic understanding of the epigenetic regulation of gene expression in cancer cells and to rapidly translate the basic discovery of the molecular mechanisms into clinical trials in patients with chronic lymphocytic leukemia (CLL). The Program consists of five highly interactive and interdependent Projects supported by three Cores. It is based on the hypothesis that aberrant methylation of specific genes plays a key role in tumor development and that reactivation of these genes can be used as an effective means to clinically arrest tumor growth. Project 1 focuses on early therapeutic trials using agents that target epigenetic modifications, and incorporate detailed pharmacokinetic and pharmacodynamic studies with the ultimate goal of re-activating genes suppressed in CLL. The development of this project is heavily dependent on the determination of target genes (Project 2 and 3), identification of histone modifications (Project 4) and importance of chromatin remodeling complexes in mediating the biologic effect of the proposed epigenetically targeted therapies. (Project 5). Project 2 is aimed at identification of novel genes in genetic subtypes of CLL silenced by methylation, correlation of the methylation profile of selected genes with clinical parameters, detailed study of the function of selected genes based upon potential importance to the pathogenesis and progression of CLL, and re-activation of these genes in CLL (interaction with Project 1). Project 3 will explore the methylation and suppression of the receptor-type protein tyrosine phosphatase (PTPRO) in CLL, PTPRO promoter methylation and reduced expression in genetic subtypes of CLL, the novel tumor suppressor function of PTPRO, elucidation of the molecular mechanisms by which DNA methylation of this gene leads to its suppression, and its re-activation in CLL (interaction with Project 1). Project 4 will focus on identification of novel sites of post-translational modifications on core histones by sensitive mass spectrometry, specific histone modifications that are associated with cancer, and characterization of the changes in histone modifications that result from the treatment of CLL patients with agents that target chromatin structure (interaction with Project 1). Project 5 will focus on biochemical characterization of the activity and substrate specificity of the Brg1 and hBrm-associated PRMT5, identification of common target genes regulated by PRMTS-containing Brg1 and hBrm chromatin remodeling complexes in CLL before and after treatment with the agents used in clinical trials (interaction with Project 1). In addition to the interdependence of all projects, the synergistic and interactive elements of the projects are also reflected in but not limited to the common use of a) reagents, b) well characterized primary CLL samples, and c) techniques & technologies (Restriction Landmark Genomic Sequencing, Bisulfite genomic sequencing, chIP assays, Real-time PCR) in order to accomplish the common goal of real-time translational research.

描述（由申请人提供）：本项目资助申请的长期目标是增进我们对癌细胞基因表达表观遗传调控的基本了解，并将分子机制的基本发现迅速转化为患者的临床试验患有慢性淋巴细胞白血病（CLL）。 该计划由三个核心支持的五个高度互动和相互依赖的项目组成。 它基于这样的假设：特定基因的异常甲基化在肿瘤发展中起着关键作用，并且这些基因的重新激活可以作为临床上阻止肿瘤生长的有效手段。 项目 1 侧重于使用针对表观遗传修饰的药物进行早期治疗试验，并结合详细的药代动力学和药效学研究，最终目标是重新激活 CLL 中抑制的基因。 该项目的发展在很大程度上取决于靶基因的确定（项目2和项目3）、组蛋白修饰的鉴定（项目4）以及染色质重塑复合物在介导所提出的表观遗传靶向疗法的生物学效应中的重要性。 （项目 5）。 项目2旨在鉴定因甲基化而沉默的CLL遗传亚型中的新基因，选定基因的甲基化谱与临床参数的相关性，根据对CLL发病机制和进展的潜在重要性详细研究选定基因的功能，以及 CLL 中这些基因的重新激活（与项目 1 相互作用）。 项目3将探索CLL中受体型蛋白酪氨酸磷酸酶（PTPRO）的甲基化和抑制、CLL基因亚型中PTPRO启动子甲基化和表达减少、PTPRO的新型抑癌功能、阐明DNA该基因的甲基化导致其抑制，并在 CLL 中重新激活（与项目 1 相互作用）。 项目 4 将重点通过敏感质谱法鉴定核心组蛋白翻译后修饰的新位点、与癌症相关的特定组蛋白修饰，以及对 CLL 患者使用以下药物治疗所导致的组蛋白修饰变化的表征：目标染色质结构（与项目 1 相互作用）。 项目 5 将重点研究 Brg1 和 hBrm 相关 PRMT5 的活性和底物特异性的生化特征，鉴定在用临床使用的药物治疗前后 CLL 中受含有 PRMTS 的 Brg1 和 hBrm 染色质重塑复合物调节的常见靶基因试验（与项目 1 交互）。 除了所有项目的相互依赖之外，项目的协同和互动元素还体现在但不限于a）试剂的共同使用，b）明确表征的初级CLL样本，以及c）技术和技术（限制地标）基因组测序、亚硫酸氢盐基因组测序、chIP 测定、实时 PCR），以实现实时转化研究的共同目标。